LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Lineage Cell Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.95−0.03 (-2.61%)
Close on Oct 19, 2026
- Market cap
- $249.13M
- P/E (TTM)
- –
- Dividend yield
- –
Lineage Cell Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Lineage Cell Therapeutics | Industry median |
|---|---|---|
| Market Cap | $240.97M | $197.05M |
| Enterprise Value | $189.02M | $106.56M |
| PS Ratio | 18.42 | 3.93 |
| PB Ratio | 3.96 | 2.14 |
| P/TBV Ratio | 12.99 | 2.46 |
Enterprise value
| Measure | Lineage Cell Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 14.45 | 2.69 |
Income (trailing twelve months)
| Measure | Lineage Cell Therapeutics | Industry median |
|---|---|---|
| Revenue | $13.08M | $57.94M |
| Operating Income | -$26.85M | -$21.44M |
| Net Income | -$32.26M | -$22.46M |
| EBITDA | -$26.11M | -$16.91M |
| EPS (Diluted) | -$0.19 | -$0.83 |
Margins
| Measure | Lineage Cell Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -205.2% | -44.5% |
| Profit Margin | -246.6% | -39.2% |
| EBITDA Margin | -199.6% | -31.3% |
| FCF Margin | -186.4% | -8.85% |
Returns
| Measure | Lineage Cell Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -59.0% | -53.1% |
| Return on Assets (ROA) | -32.7% | -41.0% |
| Return on Invested Capital (ROIC) | -262.1% | -32.0% |
| Return on Capital Employed (ROCE) | -27.3% | -37.8% |
Growth
| Measure | Lineage Cell Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 19.9% | 6.01% |
| Revenue Growth (3Y CAGR) | -0.33% | 2.25% |
| Revenue Growth (5Y CAGR) | 51.5% | 6.42% |
Balance sheet
| Measure | Lineage Cell Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $50.83M | $62.42M |
| Net Cash (Debt) | $50.83M | $15.68M |
| Net Cash Per Share | $0.20 | $0.65 |
| Equity (Book Value) | $60.92M | $48.79M |
| Book Value Per Share | $0.24 | $1.36 |
| Tangible Book Value | $18.54M | $23.06M |
| Working Capital | $44.95M | $75.77M |
Financial position
| Measure | Lineage Cell Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 6.61 | 3.30 |
| Quick Ratio | 6.44 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Lineage Cell Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$23.82M | -$12.35M |
| Capital Expenditures | -$574.00K | -$1.06M |
| Free Cash Flow | -$24.39M | -$20.28M |
| FCF Per Share | -$0.10 | -$0.41 |
Efficiency
| Measure | Lineage Cell Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.13 | 0.38 |
| Revenue Per Employee | $169.91K | $398.96K |
| Profits Per Employee | -$418.96K | -$732.08K |
| Employee Count | 77 | 73 |
Dividends and yields
| Measure | Lineage Cell Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -13.4% | -21.2% |
| FCF Yield | -10.1% | -7.64% |
Shares
| Measure | Lineage Cell Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 252,907,000 | 59,128,900 |
| Shares Change (YoY) | 11.9% | 11.1% |
| Shares Change (QoQ) | 1.45% | 0.54% |
| Float | 64,655,900 | 48,744,500 |
| Shares Held by Insiders | 74.4% | 11.8% |
| Shares Held by Institutions | 46.1% | 59.4% |
Scores
| Measure | Lineage Cell Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -3.29 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Lineage Cell Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.